Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
PI3K inhibitor |
| gptkbp:administeredBy |
oral
|
| gptkbp:CASNumber |
944396-07-0
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:hasMolecularFormula |
C18H21F3N6O2
|
| gptkbp:hasSMILES |
C1COCCN1C2=NC(=NC(=N2)N3CCOCC3)C4=NC=C(C=C4N)C(F)(F)F
|
| gptkbp:hasUNII |
8L2I2M741T
|
| https://www.w3.org/2000/01/rdf-schema#label |
BKM120
|
| gptkbp:investigatedBy |
gptkb:cancer
gptkb:glioblastoma |
| gptkbp:IUPACName |
5-(2,6-dimorpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine
|
| gptkbp:molecularWeight |
410.4 g/mol
|
| gptkbp:PubChem_CID |
16654907
CHEMBL1800257 DB11796 |
| gptkbp:status |
investigational
|
| gptkbp:synonym |
Buparlisib
|
| gptkbp:target |
gptkb:PI3K
|
| gptkbp:bfsParent |
gptkb:buparlisib
|
| gptkbp:bfsLayer |
6
|